Social determinants may limit the success of PCSK9 inhibitors, an effective treatment for hyperlipidemia in statin-intolerant patients

Abstract

A clinical decision report using: Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J. Clin. Lipidol. 2015;9(6):758-769. https://doi.org/10.1016/j.jacl.2015.08.006 for a statin-intolerant patient with hyperlipidemia.